Shankar Iyer - Intertrust CEO Board
Insider
Shankar Iyer is CEO Board of Intertrust NV
| Age | 59 |
| Phone | 31 20 521 4777 |
| Web | https://www.intertrustgroup.com |
Intertrust Management Efficiency
The company has return on total asset (ROA) of 0.0294 % which means that it generated a profit of $0.0294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0339 %, meaning that it generated $0.0339 on every $100 dollars invested by stockholders. Intertrust's management efficiency ratios could be used to measure how well Intertrust manages its routine affairs as well as how well it operates its assets and liabilities.Intertrust NV has accumulated 1.02 B in total debt with debt to equity ratio (D/E) of 1.12, which is about average as compared to similar companies. Intertrust NV has a current ratio of 1.2, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Intertrust until it has trouble settling it off, either with new capital or with free cash flow. So, Intertrust's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intertrust NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intertrust to invest in growth at high rates of return. When we think about Intertrust's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Pr Staels | Genfit | 62 | |
| Russell MS | Acumen Pharmaceuticals | 67 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Jason Treft | Merit Medical Systems | N/A | |
| Pascal Caisey | Genfit | 56 | |
| BSRT MPH | RadNet Inc | N/A | |
| Stefanie Magner | Genfit | 43 | |
| Thomas Baetz | Genfit | 51 | |
| Mark Lappe | Inhibrx | 58 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Quinn Deveraux | Inhibrx | N/A | |
| Michel Voigt | Merit Medical Systems | 52 | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| CPA Parra | Merit Medical Systems | 47 | |
| Ruth VilligerWilson | RadNet Inc | 60 | |
| Ranjan Jayanathan | RadNet Inc | 68 | |
| Neil Peterson | Merit Medical Systems | 58 | |
| BS CPA | Inhibrx | 42 | |
| Pascal Prigent | Genfit | 57 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 0.0339 | |||
| Return On Asset | 0.0294 |
Intertrust NV Leadership Team
Elected by the shareholders, the Intertrust's board of directors comprises two types of representatives: Intertrust inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intertrust. The board's role is to monitor Intertrust's management team and ensure that shareholders' interests are well served. Intertrust's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intertrust's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rogier Wijk, CFO Board | ||
| Corneel Ryde, G Counsel | ||
| Ian Rumens, Global Wealth | ||
| Cliff Pearce, Global Markets | ||
| Shankar Iyer, CEO Board | ||
| Daniel Jaffe, Managing World | ||
| Marie McNeela, Managing Guernsey | ||
| Ian Lynch, Chief Officer | ||
| Roberto Canenti, Chief Officer | ||
| Marieke Palstra, Marketing Relations |
Intertrust Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Intertrust a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0339 | |||
| Return On Asset | 0.0294 | |||
| Profit Margin | 0.05 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 2.3 B | |||
| Shares Outstanding | 88.91 M | |||
| Shares Owned By Institutions | 66.04 % | |||
| Price To Earning | 31.85 X | |||
| Price To Sales | 3.44 X | |||
| Revenue | 587.71 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Intertrust OTC Stock
If you are still planning to invest in Intertrust NV check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intertrust's history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |